{"commentary":{"count":4,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":2,"podcast":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"LiDer","nct_id":"NCT06385548","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=lider-nct06385548. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"LiDer","arms":[{"description":null,"label":"Lurbinectedin and Dostarlimab Combination Therapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-04","type":"ESTIMATED"},"conditions":["Endometrial Cancer"],"enrollment":{"count":0,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Lurbinectedin","type":"DRUG"},{"name":"Dostarlimab","type":"DRUG"}],"last_update":"2025-04-01","lead_sponsor":"Vall d'Hebron Institute of Oncology","official_title":"Phase I-II Study to Evaluate the Safety, Tolerability, and Efficacy of Lurbinectedin and Dostarlimab in Patients with Advanced/Recurrent Endometrial Cancer with Disease Progression Following Previous Platinum Chemotherapy Therapy","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2024-05-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Maximum Tolerated Dose (MTD) and Recommended Dose (RD) Determination","timeFrame":"MTD and RD will be assessed during the Phase I portion of the study, the time frame will be arround 6 months."},{"measure":"Evaluation of Lurbinectedin and Dostarlimab Combination Therapy in Advanced/Recurrent Cervical Cancer Patients","timeFrame":"This objective will be assessed during the Phase II portion of the study, the time frame will be arround 6 months."}],"references":[],"start_date":{"date":"2024-05","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer","url":"https://clinicaltrials.gov/study/NCT06385548"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/lider-nct06385548"}